CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform that mentioned sharecertificate has been reported lost by the shareholder of the company.11-08-2023
11-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release regarding Caplin Point Laboratories Limited has been recognized in Forbes Asia''s "200 Best under a Billion" list for the year 2023.11-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
In continuation to our communication dated August 03, 2023, we would like to update that the audio recording of the Earnings Call for Q1/ FY 2023-24 held today, i.e. Tuesday, August 08, 2023 at 11:00 hrs (IST) has been made available on the Company's website08-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copy of Newspaper Advertisement with respect to financial results published on August 08,2023.08-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
This is to inform mentioned shareholders has reported loss of share certificate07-08-2023
Caplin Point Q1 net profit jumps 21% to 104 crore
Consolidated revenue from operations grew by 14 per cent yoy to 395 crore07-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Corporate Action- Fixes Record Date For Dividend On 14Th September 2023
Intimation of Book Closure and Record date pursuant to Regulation 42 of the SEBI Lisitng Regulations.07-08-2023
Q1FY24 Quarterly Result Announced for Caplin Point Laboratories Ltd.
Pharmaceuticals company Caplin Point Laboratories announced Q1FY24 results: Revenue for Q1FY24 grew by 13.1% YoY to Rs 407 crore Gross margin for Q1FY24 is at 54.8% EBITDA for Q1FY24 is Rs 139 crore; EBITDA margins at 34.0% Q1FY24 PAT is at Rs 104 crore up 20.8% YoY Cash and cash equivalents at Rs 808 crore as of June 30, 2023 Cash flow from operations at Rs 88 crore for Q1FY24; Capex for Q1FY24 is at Rs 51 crore; Free cash flow for the period was Rs 37 crore Basic EPS grew by 21% to Rs 13.62 in Q1FY24 against Rs 11.21 in Q1FY23 Receivable stood at 97 days Geographical breakup of sales: LATAM & ROW 88%, US 12% Commenting on the performance, C.C. Paarthipan, Chairman, said, “We are particularly pleased with the robust growth in our Latin America business, both in terms of revenue and profitability which also resulted in robust margins. The expansion of Softgel capacity at our CP-1 site has strengthened our position in this market, with a quick payback. Coming to the US, with a strong order book, we are optimistic about achieving 40-50% revenue growth in FY24. We aim to achieve this growth through strategic new product launches and by increasing our market share for existing products. Overall, we remain committed to driving sustainable growth and delivering value to all our stakeholders.” Result PDF07-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Corporate Action-Board approves Dividend
Recommended a final dividend of INR 2.5 (125%) which is subject to the shareholders approval07-08-2023
CAPLIN POINT LABORATORIES LTD. - 524742 - Board Meeting Outcome for Outcome Of Board Meeting
Results and Final Dividend.07-08-2023